Edition:
United Kingdom

People: Atara Biotherapeutics Inc (ATRA.OQ)

ATRA.OQ on NASDAQ Stock Exchange Global Select Market

31.86USD
18 Apr 2019
Change (% chg)

$-0.72 (-2.21%)
Prev Close
$32.58
Open
$32.60
Day's High
$32.72
Day's Low
$31.16
Volume
199,055
Avg. Vol
168,819
52-wk High
$54.45
52-wk Low
$27.85

Haqq, Christopher 

Dr. Christopher M. Haqq, M.D. Ph.D. serves as Executive Vice President - Research and Development, Chief Scientific Officer of the Company. From September 2011 to August 2012, Dr. Haqq served as the Chief Executive Officer of Genomic Systems, a biotechnology company. From 2007 to September 2011, Dr. Haqq served as Vice President for Clinical Research and Development at Cougar Biotechnology, Inc., a cancer-focused biotechnology company that was acquired by Johnson & Johnson in 2009, and Johnson & Johnson’s Janssen Pharmaceutical Companies division. Prior to that time, Dr. Haqq served in drug development roles at Amgen Inc., a biotechnology company, and practiced as a medical oncologist and led a translational science laboratory as an Assistant Adjunct Professor in the Division of Hematology/Oncology at the University of California, San Francisco. Dr. Haqq received a B.S. degree from Stanford University and an M.D. and Ph.D. from Harvard Medical School.

Basic Compensation

Total Annual Compensation, USD 570,752
Restricted Stock Award, USD 2,723,500
Long-Term Incentive Plans, USD --
All Other, USD 3,768
Fiscal Year Total, USD 3,298,020

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Isaac Ciechanover

3,366,820

Utpal Koppikar

--

Joseph Newell

1,641,820

Christopher Haqq

3,298,020

Mitchall Clark

1,402,910

Gad Soffer

3,098,040
As Of  31 Dec 2017